{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:56:08Z","timestamp":1772042168630,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30971259"],"award-info":[{"award-number":["30971259"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Supportive Fund","award":["81100215"],"award-info":[{"award-number":["81100215"]}]},{"name":"General Hospital of Chinese People\u2019s Liberation Army","award":["2012FC-TSYS-3042"],"award-info":[{"award-number":["2012FC-TSYS-3042"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.thromres.2014.12.007","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T19:06:44Z","timestamp":1418152004000},"page":"449-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention\u2013 a systematic review and meta-analysis"],"prefix":"10.1016","volume":"135","author":[{"given":"Lanning","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoquan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.12.007_bb0005","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1161\/CIR.0b013e31828478ac","volume":"127","author":"Anderson","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.12.007_bb0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1160\/TH11-03-0202","article-title":"Prevalence of poor biological response to clopidogrel: a systematic review","volume":"107","author":"Mallouk","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.12.007_bb0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2014.12.007_bb0020","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.12.007_bb0025","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2014.12.007_bb0030","doi-asserted-by":"crossref","first-page":"d4588","DOI":"10.1136\/bmj.d4588","article-title":"Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis","volume":"343","author":"Bauer","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2014.12.007_bb0035","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2014.12.007_bb0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/hrt.2011.227652","article-title":"Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel","volume":"98","author":"Zabalza","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.thromres.2014.12.007_bb0265","author":"Food and Drug Administration"},{"key":"10.1016\/j.thromres.2014.12.007_bb0050","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/jth.12200","article-title":"Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study","volume":"11","author":"Jeong","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.12.007_bb0055","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease","volume":"306","author":"Mega","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2014.12.007_bb0060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jcin.2011.03.002","article-title":"High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)","volume":"4","author":"Collet","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.thromres.2014.12.007_bb0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.thromres.2011.12.038","article-title":"Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade","volume":"130","author":"Bonello","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.12.007_bb0070","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jcin.2010.05.007","volume":"3","author":"Jeong","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.thromres.2014.12.007_bb0075","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCINTERVENTIONS.110.949859","article-title":"Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention","volume":"3","author":"Hwang","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.thromres.2014.12.007_bb0080","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ahj.2011.07.026","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150mg) clopidogrel","volume":"162","author":"Alexopoulos","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2014.12.007_bb0085","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jacc.2010.07.004","article-title":"Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0090","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"Campo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0095","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis","volume":"103","author":"Giusti","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0100","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehr155","article-title":"No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting","volume":"32","author":"Sibbing","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2014.12.007_bb0105","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2014.12.007_bb0110","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ahj.2010.06.039","article-title":"Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events","volume":"160","author":"Tiroch","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2014.12.007_bb0115","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0120","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.jacc.2011.11.068","article-title":"Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study","volume":"59","author":"Price","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0125","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.amjcard.2011.05.045","article-title":"Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome","volume":"108","author":"Cuisset","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcin.2010.12.010","article-title":"Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype","volume":"4","author":"Kim","year":"2011","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.thromres.2014.12.007_bb0135","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.amjcard.2007.11.065","article-title":"Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome","volume":"101","author":"Frere","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0140","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/FPC.0b013e3282f1b2be","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G\/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients","volume":"17","author":"Giusti","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.thromres.2014.12.007_bb0145","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2014.12.007_bb0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2013.05.006","article-title":"Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients","volume":"132","author":"Zhang","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.12.007_bb0155","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1097\/BRS.0b013e3181b1c99f","article-title":"updated method guidelines for systematic reviews in the Cochrane Back Review Group","volume":"34","author":"Furlan","year":"2009","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.thromres.2014.12.007_bb0160","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0165","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1538-7836.2010.03809.x","article-title":"Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis","volume":"8","author":"Combescure","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.12.007_bb0170","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1538-7836.2012.04756.x","article-title":"Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis","volume":"10","author":"Reny","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.12.007_bb0175","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2014.12.007_bb0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2014.12.007_bb0185","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.thromres.2014.12.007_bb0190","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/hrt.2008.152660","article-title":"Emergence of the concept of platelet reactivity monitoring of response to thienopyridines","volume":"95","author":"Bonello","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.thromres.2014.12.007_bb0195","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0200","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.12.007_bb0205","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0210","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.12.007_bb0215","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1161\/CIRCULATIONAHA.113.007524","article-title":"High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study","volume":"129","author":"Montalescot","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.12.007_bb0220","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1161\/CIRCULATIONAHA.111.085464","article-title":"Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study","volume":"125","author":"Reny","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.12.007_bb0225","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0230","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.atherosclerosis.2011.04.008","article-title":"Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease","volume":"220","author":"Chen","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2014.12.007_bb0235","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.12.007_bb0240","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10928-008-9103-7","article-title":"Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease","volume":"35","author":"Ernest","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.thromres.2014.12.007_bb0245","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FJC.0b013e3181492209","article-title":"Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel","volume":"50","author":"Payne","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.thromres.2014.12.007_bb0250","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1160\/TH04-02-0105","article-title":"Pharmacokinetics of clopidogrel after administration of a high loading dose","volume":"92","author":"Taubert","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.12.007_bb0255","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/clpt.2008.20","article-title":"The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance","volume":"84","author":"Kim","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2014.12.007_bb0260","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1538-7836.2008.03050.x","article-title":"The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects","volume":"6","author":"Umemura","year":"2008","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814006471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814006471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T15:08:50Z","timestamp":1690729730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814006471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0049384814006471"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.12.007","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention\u2013 a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}